Synairgen plc
SYGGF
Other OTC0.00
USD
- -
- -
ISIN
GB00B0381Z20
Return %
Stock
S&P500
1Y
0.00
26.84
3Y
-99.92
77.03
5Y
-100.00
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Joseph Tregonning Colliver
- Full Time Employees
- 36
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Mailpoint 810 Southampton United Kingdom SO16 6YD
- IPO Date
- Jul 20, 2020
- Website
- synairgen.com
- Similar Companies
- Business
- Synairgen plc is a clinical-stage biopharmaceutical company specializing in the discovery and development of inhaled therapies for severe respiratory diseases, including viral lung infections, severe asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF). Founded in 2003 by professors from the University of Southampton, the company is headquartered in Southampton, United Kingdom, and operates primarily within the UK and global markets. Its core product is SNG001, an inhaled formulation of interferon beta (IFN-β), a naturally occurring antiviral protein designed to boost lung immune responses directly at the site of infection. SNG001 is targeted at treating severe viral lung infections, including those in mechanically ventilated patients, and has demonstrated potential clinical benefits in both outpatient and hospital settings. Synairgen provides a focused pipeline on respiratory drug discovery and development, utilizing a proprietary BioBank platform consisting of human tissue models to facilitate drug development and disease understanding. The company’s offerings include investigational inhaled therapies designed to treat severe respiratory conditions by enhancing the body’s innate antiviral response. Synairgen also collaborates strategically to advance its inhaled drug candidates and delivery technologies. Recent major developments include the completion of an £18 million funding round in early 2025, primarily supported by TFG Asset Management, to advance the Phase 2 INVENT clinical trial designed to assess the efficacy of SNG001 in mechanically ventilated patients with severe viral lung infections. Furthermore, in November 2025, Synairgen announced a strategic partnership with Aerogen Ltd., a global leader in acute care aerosol drug delivery, to develop and commercialize a bespoke aerosol device tailored to optimize the delivery of SNG001. This collaboration focuses on combining Synairgen’s antiviral drug candidate with Aerogen’s advanced aerosol technology to improve clinical outcomes for critically ill respiratory patients, including those in intensive care requiring mechanical ventilation. These developments mark significant progress in Synairgen’s strategic expansion within the respiratory biotech industry, emphasizing integrated drug-device solutions for severe respiratory infections.
Synairgen shares stay tradeable post-delisting, as top investor waives restrictions
Synairgen becomes the latest company to eye the AIM exit door
Synairgen CEO on funding phase 2 trial for SNG001 - ICYMI
Synairgen backer ready to pump £18-£19 million into phase II trial
Synairgen making substantial progress towards phase II trial
Synairgen appoints inhaled drug development expert as chairman
Synairgen making plans for phase II trial
Synairgen appoints new CFO as incumbent bows out after nearly 20 years
Synairgen hires full-time chief medical officer as drug development ramps up